Stuart A. Arbuckle - 15 Jun 2022 Form 4 Insider Report for ImmunoGen, Inc.

Role
Director
Signature
/s/ Renee Lentini, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Jun 2022
Net transactions value
+$148,280
Form type
4
Filing time
17 Jun 2022, 16:10:47 UTC
Previous filing
10 Jun 2022
Next filing
10 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Deferred Share Unit Award $0 +15,000 +31% $0.000000 63,000 15 Jun 2022 Common Stock 15,000 $0.000000 Direct F1, F2, F3
transaction IMGN Stock Option (right to buy) Award $148,280 +44,000 $3.37* 44,000 15 Jun 2022 Common Stock 44,000 $3.37 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
F2 The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date.
F3 The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
F4 Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date.